Margaret Yu, M.D., Vice President, Disease Area Leader, Prostate Cancer, in her Janssen lab.

There’s promising news in the fight against prostate cancer: According to a recent study conducted by the American Cancer Society, incidence of the disease—as well as deaths from prostate cancer—have been decreasing or stabilizing in most countries around the world.

And while the disease still remains the most common cancer in American men after skin cancer, overall outcomes are improving and “many patients are living longer lives,” explains Margaret Yu, M.D., Vice President, Disease Area Leader, Prostate Cancer, Janssen Research & Development, LLC.

PC-3 human prostate cancer cells, stained with Coomassie blue (Shutterstock)

Better screening is one reason why these statistics are improving, but treatment advancements are also helping change the landscape for prostate cancer patients.

In this interview, we sat down with Dr. Yu to learn more about the disease, who is at risk and what kind of research could potentially help lead to a cure.

To read the rest of Dr. Yu’s interview, please click here.

This article first appeared on www.jnj.com in September 2019.